Aβ immunogenic peptide carrier conjugates and methods of producing same
View Patent ↗The present invention is directed to methods of producing conjugates of Aβ peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.
1. A method of producing an immunogenic conjugate, the method comprising the steps of:
(a) adding a carboxy-terminal cysteine residue to an Aβ fragment comprising residues 1-7 of Aβ (SEQ ID NO:21);
(b) derivatizing one or more lysine residues of a CRM 197 carrier protein to generate an activated functional group on the carrier protein;
(c) reacting the peptide immunogen comprising residues 1-7 of Aβ (SEQ ID NO:21) and the carboxy-terminal cysteine residue with the carrier protein of step (b) under conditions to form a conjugate; and
(d) further reacting the conjugate of step (c) with N-acetylcysteamine to inactivate any remaining activated functional group on the carrier protein to generate the immunogenic conjugate,
wherein the immunogenic conjugate has the formula:
wherein,
C is CRM 197 ,
X d is a derivatized lysine residue of CRM 197 ,
P is the peptide immunogen covalently attached to the derivatized lysine residue via the C-terminal cysteine residue,
R is a capping molecule formed by reaction of the conjugate with N-acetylcysteamine in step (d) covalently attached to the derivatized lysine residue of CRM 197
n is an integer greater than 0, but less than or equal to 38, and
p is an integer greater than 0, but less than or equal to 38.
2. The method of claim 1 , wherein n is an integer greater than or equal to 5, but less than or equal to 25.
3. The method of claim 2 , wherein n is an integer greater than or equal to 12, but less than or equal to 15.
4. The method of claim 3 , wherein n is 12.
5. The method of claim 3 , wherein n is 14.
6. The method of claim 3 , wherein the peptide immunogen is DAEFRHD-C (SEQ ID NO:2).
7. The method of claim 1 , wherein the immunogenic conjugate has the formula:
wherein,
n is an integer greater than 0, but less than or equal to 38, and
p is an integer greater than 0, but less than or equal to 38.
8. The method of claim 7 , wherein n is 12, 14 or 15.
9. The method of claim 8 , wherein n plus p equals from 20 to 22.
10. The method of claim 7 , wherein n plus p equals from 20 to 22.